Clinical Trials
31 trialsNCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07601100 2026-05-22
Isa Iber VD
Dana-Farber Cancer Institute
Phase 1/2 Not yet recruiting
NCT07600151 2026-05-20
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Not yet recruiting
NCT07387926 2026-05-19
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT07285239 2026-05-18
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07588698 2026-05-15
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT06948084 2026-05-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07444710 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07463807 2026-05-13
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT07569757 2026-05-08
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07560449 2026-05-01
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT07513129 2026-04-21
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07542288 2026-04-21
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
The Second Affiliated Hospital of Hainan Medical University
Phase 2/3 Not yet recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07442890 2026-03-02
A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron
Henan Cancer Hospital
Phase NA Not yet recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT07072585 2025-12-31
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
Phase 2/3 Not yet recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07254416 2025-11-28
A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Not yet recruiting
NCT07247097 2025-11-25
ELDORADO
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07015021 2025-06-11
DKPD
The First Affiliated Hospital of Soochow University
Phase NA Not yet recruiting
NCT06742138 2024-12-19
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06643689 2024-11-14
TAPES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT06175702 2023-12-19
LALPh2022
PETHEMA Foundation
Not yet recruiting
NCT05909826 2023-06-18
KMM-KCd
Dong-A University Hospital
Phase 2 Not yet recruiting
NCT05581875 2022-10-17
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
Phase 1/2 Not yet recruiting